PACULit Daily Literature Update
Predicting success with reduced dosing frequency of tralokinumab in patients with moderate-to-severe atopic dermatitis
Weidinger S, Bewley A, Hong HC, Silvestre JF, Peris K, Wollenberg A, Ivens U, Soehoel A, Steffensen LA, Tindberg AM, Simpson EL. Predicting success with reduced dosing frequency of tralokinumab in patients with moderate-to-severe atopic dermatitis.
Br J Dermatol. 2025;192(3):410-419. doi:10.1093/bjd/ljae439. PMID: 39657020.
Introduction
Atopic dermatitis (AD) is a chronic inflammatory skin disease often characterized by severe itching and widespread eczematous lesions, significantly impacting patients’ quality of life. Biologic therapies targeting key cytokines have revolutionized moderate-to-severe AD management. Tralokinumab, a monoclonal antibody against IL-13, is initially administered every two weeks (Q2W) leading to substantial clinical improvements. However, optimizing long-term treatment with dose reduction strategies while maintaining efficacy is critical for patient convenience, safety, and health economics.
This post-hoc analysis of phase III ECZTRA 1 and 2 trials investigates predictive factors associated with successful maintenance of clinical response following a reduction in tralokinumab dosing frequency from every two weeks to every four weeks (Q4W) in patients with moderate-to-severe AD. Understanding these factors may facilitate personalized dose adjustment and improve long-term treatment adherence and outcomes.
Study Overview
Study Type: Post-hoc analysis of phase III randomized controlled ECZTRA 1 and 2 trials
Population: Adult patients with moderate-to-severe atopic dermatitis who achieved clinical response at week 16 on tralokinumab Q2W monotherapy
Intervention: Dose frequency reduction from tralokinumab 300 mg every 2 weeks (Q2W) to every 4 weeks (Q4W) for maintenance
Outcomes: Predictive factors for maintained response at week 52; response recapture upon relapse; immunogenicity assessment
The study applied a machine learning approach on data from responders (IGA 0/1 and/or EASI 75) at week 16 to identify the top predictors of sustained clinical response at one year. Additionally, it assessed the ability to recapture response after relapse on the reduced dose and evaluated immunogenicity rates and their clinical impact.
Key Findings
- The two top-ranked predictors for maintained response at week 52 were week-16 IGA score (76.1% predictive value) and worst daily pruritus Numeric Rating Scale (NRS) <3 at week 16 (56.5% predictive value).
- Patients with stable clinical response (both IGA 0/1 and pruritus NRS <3 for 4 consecutive weeks, weeks 12-16) had similar high maintained IGA 0/1 response rates at week 52 on either Q2W (72.0%) or reduced Q4W dosing (72.2%).
- Among patients relapsing on Q4W, 94.6% successfully recaptured treatment response upon reverting to Q2W dosing.
- Tralokinumab demonstrated low immunogenicity, with the presence of anti-drug antibodies not associated with loss of efficacy or increased adverse events.
Evidence Synthesis & Clinical Context
The post-hoc results by Weidinger et al. complement the established efficacy of tralokinumab seen in pivotal phase III ECZTRA trials and pooled analyses, which documented durable response rates on Q4W dosing across broader populations (2). This analysis refines patient selection by identifying early clinical markers predicting successful dose reduction maintenance, enhancing personalized treatment approaches.
Pooled Trial Data Comparison
- Simpson et al., 2023: In pooled ECZTRA 1 and 2 data, 42.4% of all week-16 responders maintained IGA 0/1 at week 52 on Q4W dosing (PMID: 37682422).
- Weidinger et al., 2025: Stable subgroup identified with refined predictors had a notably higher maintenance rate (72.2%), indicating potential to optimize therapy by selecting candidates for dose spacing.
Related Trial Evidence
- Silverberg et al., 2021: ECZTRA 3 trial demonstrated sustained efficacy with tralokinumab Q4W plus topical corticosteroids up to week 32 (PMID: 33000503), supporting maintenance dosing strategies.
- Paller et al., 2025: Established efficacy in patients with atopic comorbidities, confirming broad applicability of tralokinumab in clinical practice (PMID: 40555305).
Summary Table of Trial Outcomes & Predictive Model
| Study | Population | Dosing Regimen | Maintenance Response Rate | Key Predictors |
|---|---|---|---|---|
| Weidinger et al., 2025 | Stable responders (IGA 0/1 + pruritus NRS <3, weeks 12-16) | Q2W → Q4W maintenance | 72.2% maintained at week 52 | Week-16 IGA, pruritus NRS |
| Simpson et al., 2023 | All week-16 responders | Q4W maintenance | 42.4% maintained at week 52 | Not reported |
| Silverberg et al., 2021 | Moderate-to-severe AD on tralokinumab + topical corticosteroids | Q4W maintenance to week 32 | Sustained efficacy reported | Not applicable |
Clinical Implications
- Early demonstration of stable disease control (IGA 0/1 plus pruritus NRS <3 for 4 consecutive weeks) identifies patients suitable for effective dose frequency reduction without compromising efficacy.
- Clinicians can consider switching appropriate responders from Q2W to Q4W maintenance dosing to reduce treatment burden and improve adherence.
- In case of relapse during Q4W dosing, prompt resumption of Q2W therapy is effective in recapturing response, supporting a flexible and safe dosing strategy.
- Low immunogenicity and lack of adverse impact of anti-drug antibodies reinforce tralokinumab’s favorable long-term safety profile.
Strengths & Limitations
| Strengths | Limitations |
|---|---|
| Rigorous post-hoc analysis of high-quality, large phase III randomized trial data (ECZTRA 1 & 2) | Post-hoc design introduces potential bias; findings require prospective validation |
| Use of machine learning enhances predictive modeling for clinical response | Limited to adult patients with moderate-to-severe AD who were responders at predefined time points, limiting generalizability |
| Comprehensive assessment including immunogenicity and response recapture | Long-term effects beyond week 52 and real-world effectiveness not assessed |
Future Directions
Prospective clinical trials or real-world studies validating the predictive model and dose reduction strategy are needed to confirm applicability and optimize treatment algorithms. Further investigation into patient-reported outcomes and long-term durability of reduced dosing regimens will also enhance clinical decision-making.
Conclusion
Tralokinumab dosing interval can be safely and effectively extended to every 4 weeks in appropriately selected patients with moderate-to-severe atopic dermatitis achieving stable, clear/almost clear skin and low pruritus, supporting personalized maintenance therapy strategies.
Listen to the Podcast
A short discussion of today’s highlight.
References
- Weidinger S, Bewley A, Hong HC, et al. Predicting success with reduced dosing frequency of tralokinumab in patients with moderate-to-severe atopic dermatitis. Br J Dermatol. 2025 Feb 18;192(3):410-419. doi:10.1093/bjd/ljae439. PMID: 39657020.
- Simpson EL, Pink AE, Blauvelt A, et al. Tralokinumab efficacy over 1 year in adults with moderate-to-severe atopic dermatitis: pooled data from two phase III trials. Am J Clin Dermatol. 2023 Nov;24(6):939-952. doi:10.1007/s40257-023-00806-3. Epub 2023 Sep 8. PMID: 37682422; PMCID: PMC10570233.
- Silverberg JI, Toth D, Bieber T, et al. Tralokinumab plus topical corticosteroids for moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial. Br J Dermatol. 2021 Mar;184(3):450-463. doi:10.1111/bjd.19573. Epub 2021 Feb 22. PMID: 33000503; PMCID: PMC7986183.
- Paller AS, Soong W, Boguniewicz M, et al. Effect of tralokinumab on moderate-to-severe atopic dermatitis in patients with atopic comorbidities. Ann Allergy Asthma Immunol. 2025 Jun 22:S1081-1206(25)00315-1. doi:10.1016/j.anai.2025.06.022. Epub ahead of print. PMID: 40555305.
